Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1-Benzyl-4-bromopiperidine, also known by its IUPAC name 1-benzyl-4-bromopiperidine, is a chemical compound belonging to the class of piperidine derivatives. It is a brominated derivative of piperidine, a heterocyclic amine, and is commonly used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. With a variety of applications in medicinal chemistry, particularly in the development of drugs targeting the central nervous system, 1-Benzyl-4-bromopiperidine also serves as a building block in the preparation of other nitrogen-containing compounds and is a valuable tool for chemical research and development.

301665-60-1

Post Buying Request

301665-60-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

301665-60-1 Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-4-bromopiperidine is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of drugs targeting the central nervous system. Its unique structure allows for the creation of compounds with specific therapeutic properties, making it a valuable component in medicinal chemistry.
Used in Organic Compounds Synthesis:
1-Benzyl-4-bromopiperidine is used as a building block in the preparation of other nitrogen-containing compounds, facilitating the creation of a wide range of organic compounds with diverse applications in various industries.
Used in Chemical Research and Development:
As a valuable tool for chemical research and development, 1-Benzyl-4-bromopiperidine aids in the exploration of new chemical reactions and the discovery of novel compounds with potential applications in various fields.

Check Digit Verification of cas no

The CAS Registry Mumber 301665-60-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,1,6,6 and 5 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 301665-60:
(8*3)+(7*0)+(6*1)+(5*6)+(4*6)+(3*5)+(2*6)+(1*0)=111
111 % 10 = 1
So 301665-60-1 is a valid CAS Registry Number.

301665-60-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-benzyl-4-bromopiperidine

1.2 Other means of identification

Product number -
Other names 1-Benzyl-4-bromo-piperidine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:301665-60-1 SDS

301665-60-1Relevant articles and documents

Electroreductive Carbofunctionalization of Alkenes with Alkyl Bromides via a Radical-Polar Crossover Mechanism

Zhang, Wen,Lin, Song

supporting information, p. 20661 - 20670 (2020/12/23)

Electrochemistry grants direct access to reactive intermediates (radicals and ions) in a controlled fashion toward selective organic transformations. This feature has been demonstrated in a variety of alkene functionalization reactions, most of which proceed via an anodic oxidation pathway. In this report, we further expand the scope of electrochemistry to the reductive functionalization of alkenes. In particular, the strategic choice of reagents and reaction conditions enabled a radical-polar crossover pathway wherein two distinct electrophiles can be added across an alkene in a highly chemo- and regioselective fashion. Specifically, we used this strategy in the intermolecular carboformylation, anti-Markovnikov hydroalkylation, and carbocarboxylation of alkenes - reactions with rare precedents in the literature - by means of the electroreductive generation of alkyl radical and carbanion intermediates. These reactions employ readily available starting materials (alkyl halides, alkenes, etc.) and simple, transition-metal-free conditions and display broad substrate scope and good tolerance of functional groups. A uniform protocol can be used to achieve all three transformations by simply altering the reaction medium. This development provides a new avenue for constructing Csp3-Csp3 bonds.

Cyclometalated Ruthenium Catalyst Enables Ortho-Selective C–H Alkylation with Secondary Alkyl Bromides

Wang, Gang-Wei,Wheatley, Matthew,Simonetti, Marco,Cannas, Diego M.,Larrosa, Igor

supporting information, p. 1459 - 1468 (2020/05/25)

Although Ru-catalyzed meta-selective sp2 C–H alkylation with secondary alkyl halides is well established, ortho selectivity has never been achieved. We demonstrate that the use of a cyclometalated Ru-complex, RuBnN, as the catalyst results in a complete switch of the inherent meta-selectivity to ortho selectivity in the Ru-catalyzed sp2 C–H alkylation reaction with unactivated secondary alkyl halides. The high catalytic activity of RuBnN allows mild reaction conditions that result in a transformation of broad scope and versatility. Preliminary mechanistic studies suggest that a bis-cycloruthenated species is the key intermediate undergoing oxidative addition with the alkyl bromides, thus avoiding the more common SET pathway associated with meta-selectivity. Direct C–H functionalization is a powerful tool for milder and more environmentally friendly syntheses of biologically active compounds, as well as offering easy access to unexplored chemical space in drug discovery. However, major challenges remain for these methods to be widely applicable. The development of new catalysts with diverse and superior reactivity is key to address these challenges. Here, we show for the first time that cyclometalated Ru-complexes are able to catalyze the directed ortho-C–H alkylation of arenes with secondary alkyl bromides, enabling the late-stage functionalization and diversification of pharmaceuticals. The obtained regioselectivity is in stark contrast to that delivered by the commonly used arene-bound Ru-complexes, which afford exclusive meta-alkylation. Our work points a way to further rationally design next-generation Ru-catalysts with improved control over selectivity and reactivity, and a richer synthetic toolbox for chemists in the future. Here, we report the first ortho-selective sp2 C–H bond alkylation with secondary alkyl bromides in the Ru catalytic platform, enabled by cyclometalated ruthenium(II) complex RuBnN. Mechanistic studies indicate that the formation of a bis-cycloruthenated intermediate enables an oxidative addition to occur, thus avoiding the single-electron transfer (SET) pathway associated with meta-selectivity in other Ru catalytic systems. The reaction is tolerant of a variety of medicinally relevant functional groups and has been used to modify existing pharmaceuticals.

Narciclasine derivative, and preparation and application thereof in preparation of antitumor drugs

-

Paragraph 0169; 0170; 0171, (2017/04/28)

The invention provides a narciclasine derivative represented by the following structural formula I, wherein R1 is alkyl, cycloalkyl, benzyl or substituted benzyl, R2 is alkyl, cycloalkyl, benzyl or substituted benzyl, and n is an integer from 1 to 10. The narciclasine derivative is subjected to a tumor cell toxicity killing effect test, and results prove that the narciclasine derivative has strong toxicity killing effects on lung gland tumor cells, intestinal tumor cells, breast tumor cells, liver tumor cells, prostate tumor cells, melanoma tumor cells, endometrial tumor cells and neuroglia tumor cells, so the narciclasine derivative can be used for preparation of antitumor drugs. The invention provides a preparation method of the narciclasine derivative. The narciclasine derivative has a novel side-chain structure, shows excellent inhibitory activity on a variety of tumor cell strains, has drug efficacy better than that of narciclasine, allows toxic and side effects of the compound to be improved, provides new drugs for treatment of malignant tumors, and is of great clinical application value.

A cascade Aza-Cope/Aza-prins cyclization leading to piperidine derivatives

Nallasivam, Jothi L.,Fernandes, Rodney A.

, p. 2012 - 2022 (2015/03/18)

The cascade aza-Cope/aza-Prins cyclization of homoallylamines to give substituted piperidines has been explored. The use of glyoxalic acid as the carbonyl component afforded bicyclic structures as a result of the internal carboxylate anion trapping the intermediate cation. The unimolecular bis-, tris-, and tetrakis(homoallylamine)s efficiently delivered the appended bis-, tris- and tetrakis(piperidine-4-ol)s (tripod and crucifix shape, respectively) as new entities. The latter compound served as an excellent ligand in the Suzuki-Miyaura cross-coupling reaction to synthesize incrustoporin. The cascade aza-Cope/aza-Prins cyclization of homoallylamines to give substituted piperidines is described. A unimolecular tetrapiperidine derivative, which resulted from this strategy, was employed as a ligand in the Suzuki-Miyaura cross-coupling reaction of an α-iodobutenolide with an arylboronic acid in an efficient synthesis of incrustoporin and its analogues.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 301665-60-1